Chronic constipation Medical Services in China

Chronic constipation is a common functional gastrointestinal disorder characterized by persistent difficulty in passing stools, infrequent bowel movements (typically fewer than three per week), and/or a sensation of incomplete evacuation, straining, or rectal blockage—lasting for at least six months, with symptoms present for the last three months. It is not attributable to structural, metabolic, or systemic disease, nor solely explained by medication use or inadequate fiber intake. Pathophysiologically, chronic constipation arises from complex interactions among colonic motility dysfunction (e.g., slow-transit constipation), pelvic floor dyssynergia (impaired coordination of abdominal and pelvic floor muscles during defecation), visceral hypersensitivity, altered gut microbiota composition, and dysregulation of the brain-gut axis. Neurotransmitter imbalances—including reduced serotonin (5-HT) signaling and abnormal enteric nervous system activity—also contribute significantly. Epidemiologically, chronic constipation affects approximately 12–19% of the global adult population, with higher prevalence in women (up to 2.5× more common than in men), older adults (>60 years), and individuals with sedentary lifestyles. In China, community-based studies estimate prevalence at 6–15%, rising sharply with age and urbanization. Key modifiable risk factors include low dietary fiber intake (<20 g/day), chronic dehydration, physical inactivity, excessive use of laxatives (especially stimulant types), opioid or anticholinergic medications, and psychological stressors such as anxiety and depression. Non-modifiable risks include female sex, advancing age, and comorbid conditions like irritable bowel syndrome (IBS-C), diabetes mellitus, hypothyroidism, and Parkinson’s disease. Beyond physiological discomfort, chronic constipation profoundly impairs quality of life: patients report increased fatigue, abdominal bloating and pain, reduced work productivity, social withdrawal, sleep disturbances, and heightened risk of anxiety and depressive disorders. Complications may include hemorrhoids, anal fissures, fecal impaction, and overflow incontinence—particularly in frail elderly populations. Early diagnosis requires careful clinical evaluation, including Rome IV criteria assessment, exclusion of secondary causes (e.g., colonoscopy for red-flag symptoms), and, when indicated, anorectal manometry or colonic transit studies. Patient education on lifestyle modification—fiber optimization (25–35 g/day), timed toilet habits, adequate hydration (1.5–2 L/day), and daily physical activity—is foundational. Multidisciplinary management involving gastroenterologists, dietitians, and pelvic floor physiotherapists improves long-term outcomes and reduces relapse.

Chronic constipation, defined as persistent difficulty with defecation lasting ≥3 months with onset at least 6 months prior to diagnosis, is a multifactorial disorder commonly encountered in gastroenterology practice. Its pathophysiology involves disturbances in colonic transit, anorectal function, and central nervous system regulation of bowel habits. Common causes include functional disorders—most notably functional constipation (per Rome IV criteria), irritable bowel syndrome with constipation-predominant subtype (IBS-C), and opioid-induced constipation (OIC). Structural abnormalities such as colorectal neoplasms, strictures, rectoceles, or pelvic floor dyssynergia (e.g., paradoxical puborectalis contraction) account for a smaller but clinically significant proportion of cases. Neurological conditions—including Parkinson’s disease, multiple sclerosis, spinal cord injury, and autonomic neuropathy (e.g., in diabetes mellitus)—impair enteric nervous system signaling and colonic motilin release, leading to slowed transit. Endocrine and metabolic derangements are also prominent etiologies: hypothyroidism (reduced basal metabolic rate and diminished gut motilin secretion), hypercalcemia (inhibits smooth muscle contractility), hypokalemia (disrupts neuromuscular transmission), and diabetes mellitus (via autonomic neuropathy and gastroparesis). Medications constitute a major iatrogenic cause: opioids (mu-opioid receptor agonism in the myenteric plexus), anticholinergics (e.g., tricyclic antidepressants, antipsychotics), calcium channel blockers (especially verapamil and diltiazem), iron supplements, and certain antacids containing calcium or aluminum.

Triggers often precipitate or exacerbate underlying susceptibility. Acute triggers include abrupt discontinuation of laxatives (leading to rebound constipation), initiation of new medications (particularly opioids or anticholinergics), prolonged immobility (e.g., post-surgical recovery or hospitalization), dehydration (e.g., during febrile illness or inadequate oral intake), and dietary shifts—such as reduced fiber intake during travel or institutional care. Psychological stressors may trigger visceral hypersensitivity and alter brain-gut axis signaling, worsening symptoms in susceptible individuals. Pregnancy is another physiological trigger due to progesterone-mediated smooth muscle relaxation and mechanical compression by the enlarging uterus.

Risk factors encompass demographic, behavioral, and clinical domains. Advanced age (>65 years) is strongly associated with chronic constipation due to decreased physical activity, polypharmacy, reduced colonic compliance, and age-related neuronal loss in the enteric nervous system. Female sex confers higher risk—likely attributable to hormonal fluctuations, higher prevalence of pelvic floor dysfunction, and greater reporting bias. Low socioeconomic status correlates with limited access to high-fiber foods, healthcare, and education about bowel health. Sedentary lifestyle, chronic dehydration, and habitual stool suppression (e.g., ignoring urge to defecate due to workplace or environmental constraints) are modifiable behavioral risks. Psychiatric comorbidities—including depression, anxiety, and somatic symptom disorder—are both risk factors and consequences, reflecting bidirectional brain-gut interactions.

Genetic factors contribute modestly but significantly. Twin studies estimate heritability at ~30–40%. Polymorphisms in genes regulating serotonin signaling (e.g., SLC6A4 encoding the serotonin transporter 5-HTT), transient receptor potential (TRP) channels involved in mechanosensation, and genes affecting enteric neuron development (e.g., RET proto-oncogene variants) have been implicated. Familial clustering is observed in some forms of slow-transit constipation and congenital megacolon syndromes (e.g., Hirschsprung disease, though typically presenting in infancy, may have milder phenotypic variants manifesting later). Genome-wide association studies (GWAS) continue to identify loci linked to colonic motility and gut-brain axis modulation.

Environmental factors play a critical role in disease expression. Urban living—associated with processed diets low in fiber and high in fat, sedentary occupations, and disrupted circadian rhythms—increases prevalence. Socio-cultural norms around toileting privacy, time constraints, and stigma surrounding bowel habits discourage timely evacuation. Poor sanitation infrastructure and lack of private, accessible toilets (e.g., in schools, workplaces, or public transport) promote stool withholding. Chronic exposure to environmental toxins (e.g., organophosphate pesticides) may impair enteric neuronal function, though human evidence remains limited. Finally, early-life exposures—including antibiotic overuse altering gut microbiota composition, cesarean delivery (affecting initial microbial colonization), and infant feeding practices—may program long-term intestinal motility patterns via the microbiota-gut-brain axis.

Chronic constipation is a prevalent functional gastrointestinal disorder defined by persistent difficulty with defecation lasting for at least three months, with symptom onset at least six months prior to diagnosis. It affects approximately 12–19% of the general population globally, with higher prevalence among women, older adults (>65 years), and individuals with sedentary lifestyles or multiple comorbidities. From a gastroenterological perspective, chronic constipation encompasses several subtypes—including slow-transit constipation, dyssynergic defecation (pelvic floor dysfunction), and normal-transit constipation—each with distinct pathophysiological underpinnings.

Early symptoms often manifest insidiously and may be dismissed as transient or lifestyle-related. Patients commonly report a gradual onset of decreased bowel movement frequency (e.g., fewer than three spontaneous complete bowel movements per week), increased straining during ≥25% of defecations, and a subjective sensation of incomplete evacuation or anorectal blockage/obstruction in ≥25% of bowel movements. Early subjective cues include prolonged abdominal fullness after meals, mild bloating without significant distension, intermittent lower abdominal discomfort relieved temporarily by passing flatus or stool, and subtle changes in stool consistency—such as occasional passage of lumpy or hard stools (Bristol Stool Form Scale types 1–2) without overt pain. Some patients initially notice reduced urgency to defecate or diminished rectal sensation, particularly upon waking—a sign of impaired colonic motilin or serotonin-mediated signaling.

Typical symptoms reflect established pathophysiology and meet Rome IV diagnostic criteria for functional constipation when two or more of the following persist for ≥3 months: (1) straining during ≥25% of defecations; (2) lumpy or hard stools in ≥25%; (3) sensation of incomplete evacuation in ≥25%; (4) sensation of anorectal obstruction/blockage in ≥25%; (5) sensation of anorectal impaction; and (6) a feeling of insufficient defecation. Stool frequency typically declines to ≤2 spontaneous bowel movements per week. Patients frequently describe stools as small, pellet-like, or ribbon-thin—especially if associated with pelvic floor dyssynergia or rectal intussusception. Abdominal discomfort is usually dull, crampy, and localized to the left lower quadrant or suprapubic region; it tends to worsen pre-defecation and improve post-evacuation. Tenesmus—persistent, painful urge to defecate despite empty rectum—is common in dyssynergic subtypes. Nocturnal defecation is exceedingly rare and should prompt evaluation for organic pathology.

Accompanying symptoms extend beyond the anorectal axis and reflect systemic or neurogastrointestinal involvement. These include generalized fatigue, reduced appetite, early satiety, and nausea—often secondary to colonic distension-induced vagal modulation or small intestinal bacterial overgrowth (SIBO) in severe cases. Urinary symptoms such as urinary frequency, urgency, or incomplete bladder emptying may co-occur due to shared pelvic floor musculature and neural innervation (e.g., pudendal nerve). Lower back pain, particularly sacral or coccygeal, can arise from chronic straining-induced ligamentous strain or myofascial tension. Psychological comorbidities are highly prevalent: up to 40% of patients meet criteria for anxiety disorders, and 30% for major depressive disorder—likely reflecting bidirectional gut-brain axis dysregulation involving altered serotonin (5-HT4) receptor expression and microbiota-derived neuroactive metabolites. Sleep disturbances, headache, and cognitive fog are also reported, though their mechanistic links remain under investigation.

Complications arise from prolonged fecal stasis and elevated intraluminal pressures. Fecal impaction—accumulation of hardened stool in the rectosigmoid region—may lead to overflow diarrhea (paradoxical diarrhea), especially in elderly or cognitively impaired patients. Anal fissures and hemorrhoidal prolapse result from recurrent traumatic straining. Rectal mucosal prolapse or solitary rectal ulcer syndrome (SRUS) develops in chronic dyssynergia due to repeated intussusception and ischemic injury. Colonic pseudo-obstruction (Ogilvie syndrome) is a rare but life-threatening complication in hospitalized or postoperative patients. Chronic constipation independently increases risk of diverticular disease, particularly sigmoid diverticulosis, via elevated segmental intraluminal pressure. Long-standing severe constipation is associated with modestly increased colorectal cancer surveillance adherence challenges—not causality—but delays in symptom recognition may mask malignancy. Electrolyte disturbances (e.g., hyperphosphatemia, hypokalemia) may occur with chronic laxative abuse, especially stimulant laxatives.

Diagnosis relies on comprehensive clinical assessment, exclusion of secondary causes, and selective testing. Initial evaluation includes detailed history (medication review—e.g., opioids, anticholinergics, calcium channel blockers, iron supplements; dietary fiber/fluid intake; psychosocial stressors; bowel habit evolution), physical examination (abdominal palpation for fecal loading, digital rectal exam assessing anal tone, puborectalis squeeze, presence of fissures/fistulae, rectal mass, or impaired rectal sensation), and basic labs (TSH, calcium, glucose, creatinine). Rome IV criteria guide functional classification. Objective testing is reserved for refractory cases or red-flag presentations: colonic transit study (radio-opaque marker study or wireless motility capsule) differentiates slow-transit from outlet obstruction; anorectal manometry evaluates resting and squeeze pressures, rectal sensation, and balloon expulsion capacity; defecography (MRI or fluoroscopic) identifies structural abnormalities like rectocele, intussusception, or enterocele; and pelvic floor electromyography helps confirm dyssynergia. Colonoscopy is indicated for age-appropriate screening or if alarm features exist (e.g., new-onset constipation >50 years, weight loss, rectal bleeding, family history of colorectal cancer).

Differential diagnosis must rigorously exclude organic, metabolic, neurological, and pharmacological etiologies. Structural lesions include colorectal neoplasms, strictures (e.g., Crohn’s disease, radiation fibrosis), or Hirschsprung disease in younger adults with lifelong constipation. Endocrine disorders—hypothyroidism, hypercalcemia, diabetes mellitus (autonomic neuropathy), and adrenal insufficiency—require biochemical confirmation. Neurological conditions such as Parkinson’s disease, multiple sclerosis, spinal cord injury, or cauda equina syndrome often present with additional motor/sensory deficits. Medication-induced constipation is among the most common reversible causes. Irritable bowel syndrome with constipation (IBS-C) overlaps clinically but is distinguished by abdominal pain that improves with defecation and variability in stool form—unlike functional constipation, where pain is not a required feature. Other mimics include celiac disease (with malabsorption signs), chronic intestinal pseudo-obstruction, and opioid-induced bowel dysfunction (OIBD), which warrants specific pharmacologic management (e.g., peripheral mu-opioid receptor antagonists). Accurate subtyping directs targeted therapy—biofeedback for dyssynergia, prokinetics for slow-transit, and behavioral interventions for lifestyle-related contributors.

Chronic constipation, defined as persistent or recurrent symptoms of difficult, infrequent, or incomplete defecation lasting ≥12 weeks within the preceding 12 months (Rome IV criteria), is a prevalent functional gastrointestinal disorder affecting approximately 14% of adults globally. In gastroenterology practice, management prioritizes symptom relief, restoration of physiological bowel habits, and prevention of complications such as fecal impaction, rectal prolapse, or megarectum. A stepwise, patient-centered approach—integrating conservative measures, pharmacotherapy, and, rarely, surgical intervention—is standard in digestive medicine departments worldwide, including specialized centers in China.

Conservative treatment forms the cornerstone of initial management and should be sustained for at least 8–12 weeks before reassessing efficacy. Dietary modification emphasizes gradual increase in non-fermentable, insoluble fiber (e.g., wheat bran, psyllium husk) to 25–30 g/day, coupled with adequate hydration (1.5–2 L of water daily) to prevent stool hardening. Behavioral interventions include scheduled toilet time—ideally 15–20 minutes after breakfast—to leverage the gastrocolic reflex—and proper positioning (squatting or footstool-assisted forward-leaning posture) to optimize pelvic floor relaxation and anorectal angle. Biofeedback therapy is strongly recommended for patients with dyssynergic defecation, demonstrated by abnormal electromyographic patterns during simulated evacuation; evidence shows ≥70% symptom improvement after 4–6 weekly sessions conducted by trained physiotherapists or gastroenterology nurses. Physical activity—such as brisk walking ≥30 minutes five times weekly—enhances colonic transit via autonomic modulation and reduces visceral adiposity-related motilin suppression.

When conservative strategies fail, pharmacologic therapy is initiated based on pathophysiology and safety profile. First-line agents include osmotic laxatives: polyethylene glycol 3350 (17 g/day, titrated to effect) remains the gold-standard due to its electrolyte-neutral action, minimal systemic absorption, and favorable long-term safety. Second-line options include sodium picosulfate (a stimulant prodrug activated by colonic flora) and lactulose (0.5–2 g TID), though the latter may cause bloating and flatulence. For refractory cases with documented slow-transit constipation, newer agents are increasingly utilized: prucalopride (2 mg daily), a highly selective 5-HT4 receptor agonist, accelerates colonic transit and improves spontaneous bowel movement frequency in >60% of patients after 4 weeks. Lubiprostone (24 mcg BID), a chloride channel activator, enhances intestinal fluid secretion and is particularly effective in opioid-induced constipation and female-predominant chronic constipation. Linaclotide (290 mcg daily) and plecanatide (3 mg daily), guanylate cyclase-C agonists, promote fluid secretion and reduce visceral hypersensitivity—both demonstrate robust efficacy in clinical trials and are approved in China’s National Reimbursement Drug List since 2021. All medications require individualized dosing, monitoring for electrolyte shifts (especially in elderly or renally impaired patients), and avoidance of chronic stimulant laxative overuse (e.g., senna, bisacodyl), which risks melanosis coli and potential enteric neuropathy.

Surgical intervention is reserved for <5% of patients with severe, medically refractory constipation and objective evidence of pathology. Indications include confirmed colonic inertia (transit study showing >70% radiopaque markers retained at 120 hours), outlet obstruction unresponsive to biofeedback, or structural anomalies (e.g., rectocele >3 cm with enterocele, internal rectal intussusception). Procedures performed in high-volume Chinese centers include laparoscopic total colectomy with ileorectal anastomosis—associated with 65–75% long-term success but carrying risks of postoperative diarrhea (20–30%), small-bowel obstruction (5–8%), and reduced quality-of-life scores in up to 25% due to altered bowel control. For outlet dysfunction, transanal minimally invasive surgery (TAMIS) for rectocele repair or stapled transanal rectal resection (STARR) may be considered, though STARR carries higher complication rates (e.g., bleeding, stenosis, de novo incontinence) and is now used selectively following rigorous preoperative pelvic floor MRI and dynamic defecography. Surgery is never undertaken without multidisciplinary consensus involving gastroenterologists, colorectal surgeons, and pelvic floor specialists.

China offers distinct advantages in chronic constipation management. First, integrated Traditional Chinese Medicine (TCM) modalities—such as acupuncture at ST25 (Tianshu) and CV6 (Qihai), and herbal formulas like Maziren Wan (Apricot Kernel Seed Pill)—are routinely combined with Western protocols in Class III-A hospitals, with randomized trials demonstrating synergistic improvement in colonic transit time and symptom scores. Second, nationwide digital health infrastructure enables remote symptom tracking via AI-powered apps linked to electronic medical records, facilitating real-time medication adherence monitoring and timely teleconsultations. Third, China’s centralized drug procurement policy has reduced costs of prucalopride and linaclotide by >40%, improving accessibility. Finally, standardized national guidelines (CMA 2023 Consensus on Functional Constipation) ensure uniform diagnostic workup—including validated questionnaires (PAC-SYM, PAC-QOL), colonic transit scintigraphy, and high-resolution anorectal manometry—across tiered healthcare facilities.

Recovery and long-term maintenance emphasize sustainability. Patients should maintain fiber intake and hydration indefinitely, avoid prolonged straining, and continue scheduled toileting even after symptom resolution. Follow-up visits every 3–6 months allow reassessment of medication need, adjustment of lifestyle strategies, and screening for red-flag symptoms (e.g., unintentional weight loss, rectal bleeding, iron-deficiency anemia) that warrant colonoscopy. Psychological support is integral: anxiety and depression correlate strongly with symptom severity, and cognitive behavioral therapy (CBT) delivered by hospital-based psychologists improves treatment adherence and reduces healthcare utilization. Importantly, patients must understand that chronic constipation is a relapsing condition—not cured but effectively managed—requiring active partnership with their gastroenterology team. With comprehensive, evidence-based care, >85% of patients achieve meaningful symptom reduction and improved quality of life.